Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
VISTA PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
VISTA PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
VISTA PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 14 | 314 | - | |
Low | Rs | 7 | 226 | - | |
Sales per share (Unadj.) | Rs | 0.3 | 93.4 | - | |
Earnings per share (Unadj.) | Rs | -1.5 | -23.5 | - | |
Cash flow per share (Unadj.) | Rs | -1.3 | -19.5 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 8.1 | 73.3 | - | |
Shares outstanding (eoy) | m | 37.56 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 39.1 | 2.9 | 1,352.7% | |
Avg P/E ratio | x | -6.9 | -11.5 | 60.4% | |
P/CF ratio (eoy) | x | -7.8 | -13.9 | 56.2% | |
Price / Book Value ratio | x | 1.3 | 3.7 | 34.9% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 393 | 45,603 | 0.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 5 | 2,862 | 0.2% | |
Avg. sales/employee | Rs Th | 0 | 3,671.4 | - | |
Avg. wages/employee | Rs Th | 0 | 666.7 | - | |
Avg. net profit/employee | Rs Th | 0 | -925.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 10 | 15,761 | 0.1% | |
Other income | Rs m | 4 | 110 | 3.6% | |
Total revenues | Rs m | 14 | 15,872 | 0.1% | |
Gross profit | Rs m | -44 | -2,731 | 1.6% | |
Depreciation | Rs m | 6 | 680 | 0.9% | |
Interest | Rs m | 12 | 427 | 2.8% | |
Profit before tax | Rs m | -59 | -3,728 | 1.6% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -2 | 233 | -0.9% | |
Profit after tax | Rs m | -57 | -3,971 | 1.4% | |
Gross profit margin | % | -442.7 | -17.3 | 2,554.6% | |
Effective tax rate | % | 3.6 | -6.2 | -58.4% | |
Net profit margin | % | -563.9 | -25.2 | 2,238.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 238 | 11,544 | 2.1% | |
Current liabilities | Rs m | 141 | 6,495 | 2.2% | |
Net working cap to sales | % | 963.0 | 32.0 | 3,006.2% | |
Current ratio | x | 1.7 | 1.8 | 94.9% | |
Inventory Days | Days | 207 | 111 | 186.3% | |
Debtors Days | Days | 40,902 | 124 | 33,001.7% | |
Net fixed assets | Rs m | 296 | 6,729 | 4.4% | |
Share capital | Rs m | 75 | 73 | 102.6% | |
Net worth | Rs m | 306 | 12,371 | 2.5% | |
Long term debt | Rs m | 52 | 4,347 | 1.2% | |
Total assets | Rs m | 534 | 23,369 | 2.3% | |
Interest coverage | x | -3.8 | -7.7 | 49.7% | |
Debt to equity ratio | x | 0.2 | 0.4 | 48.2% | |
Sales to assets ratio | x | 0 | 0.7 | 2.8% | |
Return on assets | % | -8.3 | -15.2 | 54.9% | |
Return on equity | % | -18.5 | -32.1 | 57.7% | |
Return on capital | % | -13.1 | -19.8 | 65.9% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -17 | 1,345 | -1.3% | |
From Investments | Rs m | -13 | -413 | 3.1% | |
From Financial Activity | Rs m | 31 | 3,945 | 0.8% | |
Net Cashflow | Rs m | 1 | 4,878 | 0.0% |
Compare VISTA PHARMA With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare VISTA PHARMA With: ZENITH HEALTH SANDU PHARMA OMKAR PHARMACHEM TRIDENT LIFELINE AURO LAB.
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.